Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple myeloma (MM). Minimum residual disease (MRD) has been the main method in recent years, and it’s the next frontier in MM. The main tools used are multicolour flow cytometry and next-generation sequencing.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content